| The stdudy was amied at learning the clinically relevant factors of children with idiopathic short stature(ISS), observing the clinical efficacy and safety of recombinant human growth hormone(r-hGH), and probing into the relationship among the growth-promoting effect of r-h GH, insulin-like growth factor-1(IGF-1) and insulin-like growth factor binding protein-3(IGFBP-3).Methods 1. Using the self-made "idiopathic short stature children related factors questionnaire" to retrospectively survey the 144 cases of children with ISS who was diagnosed and treated in our hospital for nearly four years,and descriptive analysis of the clinical factors; 2. Selecting 67 cases of children with ISS who have accepted the treatment with r-hGH(at a dose of 0.15 IU / kg ? d) up to 12 months to respectively measure the height, weight, fasting blood glucose, thyroid function, IGF-1 and IGFBP-3, etc.at before treatment and every 3 months after treatment, and determine the bone age at before treatment and after the every six months,and getting through the selfmade "idiopathic short stature children receiving r-h GH treatment follow-up table" to record; 3. Statistical treatment: taking homogeneity of variance test, repeated measures analysis of variance, rank sum test, linear correlation analysis and other statistical methods to research the clinical effects and safety of r-hGH,and the relation of the growth-promoting effect of r-h GH, IGF-1and IGFBP-3.Results 1. Descriptive analysis:(1) Basic situation: There were 84 male children from the 144 cases,and the rest 60 cases was female, the sex ratio was 1.4: 1; Age range from 3 to 16 years, and the median is 9.1 years. The proportion of doctor age which was form 6 years old to 11 years old accounted for 52.78%; The proportion of children who lived in rural accounted for 44.44%;(2) Parents situation:The proportion of fathers height which was P25~P50 accounted for 38.19%, and that less than or equal to P25 accounted for 33.33%; The proportion of mothers height which was P25~P50 accounted for 36.11%, and that less than or equal to P25 accounted for 43.05%;(3) ISS children living habits: The proportion of Sleeping time after 11:30 was 47.22%, the picky eaters and partial eclipse was 54.86%, and The daily exercise which was less than 30 min is 61.11%。2. The height and the growth rate of children with idiopathic short stature who have received the treatment with r-hGH was rasied compared with the previous, and the difference was statistically significant(P <0.05); But the weight and the bone age were no significant increased, and the difference was not statistically significant;The adverse reaction rate was 17.91%, and all were back to normal after symptomatic treatment. 3. The changes of the IGF-1 and the IGFBP-3 which was at 3,6,9,12 months after treatment was increased than before treatment, and the difference was statistically significant(P<0.05). The IGF-1 and IGFBP-3 before treatment was negatively correlated with the increase of growth rate at 3,6,9,12 months after treatment(P <0.05), and the increase of IGF-1 and IGFBP-3 at 3,6,9,12 months after treatment was positively correlation with the growth rate added value at the same period.Conclusion 1. In the survey, the numerous of children with ISS come from rural areas, and that the height of children,s parents is in lower-middle height occupy great majority; and that the extent of parents’ education is below the junior-senior high and the jop is farmer and self-employed are in the majority; the presence of bad eating habits, sleeping time after 23:30 minutes and the daily amount of exercise less than 30 minute is in majority; 2. The r-hGH which use to treatment idiopathic short stature is safe and effective in observation period; 3. The IGF-1 and IGFBP-3 may help predict the efficacy of r-hGH treatment in ISS children. |
PDF Full Text Request